The latest price target for NovoCure (NASDAQ:NVCR) was reported by Wells Fargo on May 4, 2026. The analyst firm set a price target for $17.00 expecting NVCR to rise to within 12 months (a possible 0.89% upside). 12 analyst firms have reported ratings in the last year.

The latest analyst rating for NovoCure (NASDAQ:NVCR) was provided by Wells Fargo, and NovoCure maintained their equal-weight rating.

The last upgrade for NovoCure Ltd happened on December 2, 2024 when Evercore ISI Group raised their price target to $30. Evercore ISI Group previously had an in-line for NovoCure Ltd.

The last downgrade for NovoCure Ltd happened on July 25, 2025 when Wells Fargo changed their price target from $40 to $14.5 for NovoCure Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NovoCure, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NovoCure was filed on May 4, 2026 so you should expect the next rating to be made available sometime around May 4, 2027.

While ratings are subjective and will change, the latest NovoCure (NVCR) rating was a maintained with a price target of $13.50 to $17.00. The current price NovoCure (NVCR) is trading at is $16.85, which is within the analyst’s predicted range.